Key Highlights
- Worldwide Healthcare Trust PLC (LSE:WWH) fell 3.63% on 8 October 2026.
- US healthcare stocks were weaker ahead of Thursday's open after the pharmaceutical industry sued US health authorities over drug pricing.
- The trust bought back 1,137,845 shares at 369.15p on 7 October under its buyback authority.
- Eli Lilly has been the trust's largest holding, and the portfolio held 51 positions at the end of May 2026.
- Leverage of about 12.5% at the end of its financial year amplifies moves in the portfolio.
Worldwide Healthcare Trust Under Pressure
Shares in Worldwide Healthcare Trust PLC (LSE:WWH) fell 3.63% on Thursday 8 October 2026. The closed-end fund, one of the largest specialist healthcare trusts in the UK, invests across pharmaceuticals, biotechnology, medical devices and healthcare services worldwide.
The trust is a constituent of the FTSE 250 index. Its portfolio is managed by OrbiMed, led by Sven Borho and Trevor Polischuk, while Frostrow Capital acts as company secretary.
Key Reasons Behind the 3.63% Fall
Weakness in US healthcare shares was the main driver. Healthcare stocks fell ahead of the Wall Street open on Thursday, and some large biotech names saw sharp pre-market losses. PhRMA, the main US pharmaceutical lobby group, sued the Department of Health and Human Services and Secretary Robert F. Kennedy Jr. over most-favoured-nation drug pricing. The legal fight raises uncertainty over how much drug companies will be able to charge in the US, their most profitable market.
Enforcement risk also rose. The US Department of Justice listed breaches of the Federal Food, Drug, and Cosmetic Act as a priority in its Fraud crackdown, which could increase legal scrutiny of drug and device makers.
Rates and Leverage amplified the move. Federal Reserve minutes showed most officials expect another rate rise, keeping bond yields high. Higher rates weigh on biotech valuations, and WWH has a meaningful biotech tilt. The trust ended its last financial year with leverage of about 12.5%, which magnifies gains and losses in the underlying portfolio.
Why Investors Are Watching WWH
Worldwide Healthcare Trust had a strong financial year to 31 March 2026, delivering NAV and share price total returns of 10.0% and 13.1%, well ahead of its benchmark's 1.8%. That marked a return to form after a difficult prior year, even though healthcare stocks remained under pressure from US drug pricing and Tariff uncertainty for much of the period. Since its launch in April 1995, the trust has generated average annual NAV total returns of 13.3%, compared with 11.0% for its benchmark.
The managers favour innovation and growth, particularly in biotechnology, with selective emerging markets exposure and a proprietary Biotech M&A Basket designed to benefit from takeovers. They believe attractive biotech valuations, high levels of innovation and large pharmaceutical companies' looming Patent cliffs should continue to drive deal activity. Eli Lilly, a leader in obesity treatments, has been the trust's largest holding.
Buybacks Support the Shares
The board has been actively buying back shares to manage the discount to net asset value. On 7 October, the trust bought 1,137,845 shares at 369.15p each into treasury under the authority granted at its July 2026 annual general meeting. Buybacks at a discount add to NAV per share for remaining shareholders and can help limit share price falls during volatile periods.
The trust also kept its final Dividend steady for 2026. Over the past year, its shares have traded in a range of roughly 293p to 397p.
What to Watch Next
Investors will follow the US drug pricing lawsuit, Interest Rate decisions and third-quarter Earnings from large pharmaceutical and biotech companies later in October. Takeover activity in biotech will also be key, since M&A has been a major source of gains for the trust. Online discussion among UK investors has focused on whether the discount and buybacks create a good entry point after Thursday's fall.
Worldwide Healthcare Trust PLC (LSE:WWH) remains a core vehicle for UK investors seeking global healthcare exposure. The 3.63% drop reflects sector-wide policy risk rather than problems specific to the trust.






Please wait processing your request...